Endo International plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENDP research report →
Companywww.endo.com
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections.
- CEO
- Blaise Coleman
- IPO
- 2014
- Employees
- 3,103
- HQ
- Dublin, IE
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.15
- P/S
- 0.00
- P/B
- -0.07
- EV/EBITDA
- 6.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 59.21%
- Op Margin
- 0.53%
- Net Margin
- -19.01%
- ROE
- 60.16%
- ROIC
- 0.22%
Growth & Income
- Revenue
- $2.99B · 3.10%
- Net Income
- $-569,081,000 · -409.38%
- EPS
- $-2.44 · -408.86%
- Op Income
- $15.75M
- FCF YoY
- 202.79%
Performance & Tape
- Beta
- 1.15
Get TickerSpark's AI analysis on ENDP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 15, 22 | Tursi James Patrick | sell | 280,373 |
| Mar 30, 22 | Barry Patrick A | other | 42,341 |
| Mar 29, 22 | Barry Patrick A | other | 16,957 |
| Mar 30, 22 | Barry Patrick A | other | 4,975 |
| Mar 29, 22 | Barry Patrick A | other | 4,141 |
| Mar 29, 22 | Raciti Frank B. | other | 965 |
| Mar 29, 22 | Maletta Matthew Joseph | other | 34,414 |
| Mar 29, 22 | Maletta Matthew Joseph | other | 10,179 |
| Mar 30, 22 | Bradley Mark T. | other | 26,805 |
| Mar 29, 22 | Bradley Mark T. | other | 10,735 |
Our ENDP Coverage
We haven't published any research on ENDP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENDP Report →